V
7.38
0.34 (4.83%)
| 前收盘价格 | 7.04 |
| 收盘价格 | 7.00 |
| 成交量 | 66,303 |
| 平均成交量 (3个月) | 747,783 |
| 市值 | 24,142,046 |
| 价格/销量 (P/S) | 132.61 |
| 股市价格/股市净资产 (P/B) | 0.460 |
| 52周波幅 | |
| 利润日期 | 10 Aug 2023 - 14 Aug 2023 |
| 营业利益率 (TTM) | -15,202.38% |
| 稀释每股收益 (EPS TTM) | -0.930 |
| 季度收入增长率 (YOY) | 10.50% |
| 总债务/股东权益 (D/E MRQ) | 0.19% |
| 流动比率 (MRQ) | 4.35 |
| 营业现金流 (OCF TTM) | -33.97 M |
| 杠杆自由现金流 (LFCF TTM) | -17.00 M |
| 资产报酬率 (ROA TTM) | -33.14% |
| 股东权益报酬率 (ROE TTM) | -56.54% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | VYNE Therapeutics Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.8
| 分析师共识 | -3.5 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 3.0 |
| 平均 | -0.75 |
|
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 9.07% |
| 机构持股比例 | 51.02% |
| 52周波幅 | ||
| 中 | 4.50 (-39.02%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Apr 2025 | 4.50 (-39.02%) | 购买 | 1.85 |
| 06 Mar 2025 | 5.75 (-22.09%) | 购买 | 2.33 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合